Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 238

1.

Overprescribing of antibiotics by UK ophthalmologists.

Fayers T, Loh GK, Cordeiro MF, Lee V, Jain R, Fayers PM.

Eye (Lond). 2017 Sep 8. doi: 10.1038/eye.2017.191. [Epub ahead of print] No abstract available.

PMID:
28885604
2.

The applicability of a weight loss grading system in cancer cachexia: a longitudinal analysis.

Vagnildhaug OM, Blum D, Wilcock A, Fayers P, Strasser F, Baracos VE, Hjermstad MJ, Kaasa S, Laird B, Solheim TS; European Palliative Care Cancer Symptom study group.

J Cachexia Sarcopenia Muscle. 2017 Jun 18. doi: 10.1002/jcsm.12220. [Epub ahead of print]

3.

A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer.

Solheim TS, Laird BJA, Balstad TR, Stene GB, Bye A, Johns N, Pettersen CH, Fallon M, Fayers P, Fearon K, Kaasa S.

J Cachexia Sarcopenia Muscle. 2017 Jun 14. doi: 10.1002/jcsm.12201. [Epub ahead of print]

4.

The relationship between pro-inflammatory cytokines and pain, appetite and fatigue in patients with advanced cancer.

Paulsen Ø, Laird B, Aass N, Lea T, Fayers P, Kaasa S, Klepstad P.

PLoS One. 2017 May 25;12(5):e0177620. doi: 10.1371/journal.pone.0177620. eCollection 2017.

5.

Randomised clinical trial of early specialist palliative care plus standard care versus standard care alone in patients with advanced cancer: The Danish Palliative Care Trial.

Groenvold M, Petersen MA, Damkier A, Neergaard MA, Nielsen JB, Pedersen L, Sjøgren P, Strömgren AS, Vejlgaard TB, Gluud C, Lindschou J, Fayers P, Higginson IJ, Johnsen AT.

Palliat Med. 2017 May 1:269216317705100. doi: 10.1177/0269216317705100. [Epub ahead of print]

PMID:
28494643
6.

Erratum to: Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format.

Norman R, Viney R, Aaronson NK, Brazier JE, Cella D, Costa DSJ, Fayers PM, Kemmler G, Peacock S, Pickard AS, Rowen D, Street DJ, Velikova G, Young TA, King MT.

Qual Life Res. 2017 Aug;26(8):2247-2248. doi: 10.1007/s11136-017-1546-0. No abstract available.

PMID:
28337638
7.

Development of the EORTC QLQ-CAX24, A Questionnaire for Cancer Patients With Cachexia.

Wheelwright SJ, Hopkinson JB, Darlington AS, Fitzsimmons DF, Fayers P, Balstad TR, Bredart A, Hammerlid E, Kaasa S, Nicolatou-Galitis O, Pinto M, Schmidt H, Solheim TS, Strasser F, Tomaszewska IM, Johnson CD; EORTC Quality of Life Group.

J Pain Symptom Manage. 2017 Feb;53(2):232-242. doi: 10.1016/j.jpainsymman.2016.09.010. Epub 2016 Nov 1.

PMID:
27810567
8.

Sensitivity and responsiveness of the patient-reported TED-QOL to rehabilitative surgery in thyroid eye disease.

Fayers T, Fayers PM, Dolman PJ.

Orbit. 2016 Dec;35(6):328-334. Epub 2016 Sep 6.

PMID:
27599688
9.

Using Linear Equating to Map PROMIS(®) Global Health Items and the PROMIS-29 V2.0 Profile Measure to the Health Utilities Index Mark 3.

Hays RD, Revicki DA, Feeny D, Fayers P, Spritzer KL, Cella D.

Pharmacoeconomics. 2016 Oct;34(10):1015-22. doi: 10.1007/s40273-016-0408-x.

10.

Erratum to: Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format.

Norman R, Viney R, Aaronson NK, Brazier JE, Cella D, Costa DS, Fayers PM, Kemmler G, Peacock S, Pickard AS, Rowen D, Street DJ, Velikova G, Young TA, King MT.

Qual Life Res. 2016 Sep;25(9):2401. No abstract available.

PMID:
27060090
11.

Erratum to: QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30.

King MT, Costa DSJ, Aaronson NK, Brazier JE, Cella DF, Fayers PM, Grimison P, Janda M, Kemmler G, Norman R, Pickard AS, Rowen D, Velikova G, Young TA, Viney R.

Qual Life Res. 2016 Oct;25(10):2683. doi: 10.1007/s11136-016-1260-3. No abstract available.

PMID:
27060088
12.

QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30.

King MT, Costa DS, Aaronson NK, Brazier JE, Cella DF, Fayers PM, Grimison P, Janda M, Kemmler G, Norman R, Pickard AS, Rowen D, Velikova G, Young TA, Viney R.

Qual Life Res. 2016 Mar;25(3):625-36. doi: 10.1007/s11136-015-1217-y. Epub 2016 Jan 20. Erratum in: Qual Life Res. 2016 Oct;25(10):2683. Qual Life Res. 2016 Oct;25(10 ):2683.

PMID:
26790428
13.

The Edmonton Symptom Assessment System: Poor performance as screener for major depression in patients with incurable cancer.

Brenne E, Loge JH, Lie H, Hjermstad MJ, Fayers PM, Kaasa S; European Palliative Care Research Collaborative (EPCRC).

Palliat Med. 2016 Jun;30(6):587-98. doi: 10.1177/0269216315620082. Epub 2016 Jan 13.

PMID:
26763008
14.

Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format.

Norman R, Viney R, Aaronson NK, Brazier JE, Cella D, Costa DS, Fayers PM, Kemmler G, Peacock S, Pickard AS, Rowen D, Street DJ, Velikova G, Young TA, King MT.

Qual Life Res. 2016 Mar;25(3):637-49. doi: 10.1007/s11136-015-1115-3. Epub 2015 Sep 5. Erratum in: Qual Life Res. 2016 Sep;25(9):2401. Qual Life Res. 2017 Mar 23;:.

PMID:
26342928
15.

Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust.

Giesinger JM, Kieffer JM, Fayers PM, Groenvold M, Petersen MA, Scott NW, Sprangers MA, Velikova G, Aaronson NK; EORTC Quality of Life Group.

J Clin Epidemiol. 2016 Jan;69:79-88. doi: 10.1016/j.jclinepi.2015.08.007. Epub 2015 Sep 28.

16.

Symptom Clusters in Advanced Cancer Patients: An Empirical Comparison of Statistical Methods and the Impact on Quality of Life.

Dong ST, Costa DS, Butow PN, Lovell MR, Agar M, Velikova G, Teckle P, Tong A, Tebbutt NC, Clarke SJ, van der Hoek K, King MT, Fayers PM.

J Pain Symptom Manage. 2016 Jan;51(1):88-98. doi: 10.1016/j.jpainsymman.2015.07.013. Epub 2015 Aug 21.

PMID:
26300025
17.

Genetic and Non-genetic Factors Associated With Constipation in Cancer Patients Receiving Opioids.

Laugsand EA, Skorpen F, Kaasa S, Sabatowski R, Strasser F, Fayers P, Klepstad P.

Clin Transl Gastroenterol. 2015 Jun 18;6:e90. doi: 10.1038/ctg.2015.19.

18.

Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: A pooled analysis of 557 trials.

Efficace F, Fayers P, Pusic A, Cemal Y, Yanagawa J, Jacobs M, la Sala A, Cafaro V, Whale K, Rees J, Blazeby J; European Organization for Research and Treatment of Cancer Quality-of-Life Group (Patient-Reported Outcome Measurements Over Time in Oncology Registry).

Cancer. 2015 Sep 15;121(18):3335-42. doi: 10.1002/cncr.29489. Epub 2015 Jun 16.

19.

Quality of life and symptom assessment in randomized clinical trials of bladder cancer: A systematic review.

Feuerstein MA, Jacobs M, Piciocchi A, Bochner B, Pusic A, Fayers P, Blazeby J, Efficace F; Patient-Reported Outcome Measurements Over Time In Oncology-PROMOTION Registry.

Urol Oncol. 2015 Jul;33(7):331.e17-23. doi: 10.1016/j.urolonc.2015.04.002. Epub 2015 May 5. Review.

20.

Specifying the target difference in the primary outcome for a randomised controlled trial: guidance for researchers.

Cook JA, Hislop J, Altman DG, Fayers P, Briggs AH, Ramsay CR, Norrie JD, Harvey IM, Buckley B, Fergusson D, Ford I, Vale LD; DELTA group.

Trials. 2015 Jan 15;16:12. doi: 10.1186/s13063-014-0526-8.

Supplemental Content

Loading ...
Support Center